Clinical Trials Logo
  1. Home
  2. Colorectal Neoplasms Malignant
  3. NCT05155124

Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC

Colorectal Neoplasms Malignant Clinical Trial

Official title:
Safety of Cetuximab in Combination With Trifluridin Tipiracil in the Third-line Treatment of RASwt Metastatic Colorectal Cancer

Clinical Trial Summary

This was a single-arm, prospective study to investigate the safety of cetuximab in combination with trifluridin tipiracil (TAS-102) in the third-line treatment of Chinese patients with RAS wild-type mCRC.

Clinical Trial Description

This was a single-arm, prospective study to investigate the safety of cetuximab in combination with trifluridin tipiracil (TAS-102) in the third-line treatment of Chinese patients with RAS wild-type mCRC. Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks; trifluridin tipiracil will be administered in a dose de-escalation design: dose level 1: 35 mg/m2 twice daily on days 1-5 once every 2 weeks; after 1 cycle will be observed, and if ≤ 2 patients experience DLT, this dose level will be the recommended phase II dose; if ≥ 3 patients experience DLT, additional 6 patients will receive dose level 0. ( Dose level 0: 30 mg/m2, twice daily, Days 1-5, once every 2 weeks;) If ≤ 2 individuals experience DLT, this dose level is the recommended Phase II dose; if ≥ 3 individuals experience DLT, the study will be stopped. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05155124
Study type Interventional
Source Wuhan Union Hospital, China
Contact Hongli Liu, PhD
Phone +86-027-85871962
Email hongli_liu@hust.edu.cn
Status Recruiting
Phase Phase 1
Start date September 2022
Completion date April 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04712292 - Effects of COVID-19 Pandemic on the Outcomes of Colorectal Cancer
Active, not recruiting NCT03775980 - CIRSE Emprint Microwave Ablation Registry
Recruiting NCT06050447 - Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
Active, not recruiting NCT03993626 - A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer Phase 1/Phase 2
Recruiting NCT06314971 - Predicting Local and Distant Recurrence in T1 Colorectal Cancer
Recruiting NCT06342440 - Early Detection of Advanced Adenomas and Colorectal Cancer
Recruiting NCT05853094 - Postoperative Effects of Different Enterostomy Approaches N/A
Recruiting NCT06200831 - Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases N/A
Recruiting NCT02758951 - Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases Phase 2/Phase 3
Recruiting NCT03686254 - The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM Phase 2/Phase 3
Recruiting NCT05278351 - Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC Phase 2
Terminated NCT04873895 - TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC) Phase 1
Completed NCT04002128 - Tracheal Colonization and Outcome After Major Abdominal Cancer Surgery N/A
Recruiting NCT06208371 - Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM Phase 3
Not yet recruiting NCT05129774 - Chemoradiotherapy Sequenced Radical Surgery for Colorectal Cancer With PALNM N/A
Completed NCT06410729 - Significance of Benign Lymph Node Enlargement in Colorectal Cancer
Completed NCT03507699 - Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer Phase 1
Active, not recruiting NCT03581890 - Socioeconomic Position in Acute Colorectal Cancer Surgery
Recruiting NCT05138094 - LIVACOR Trial: Minimally Invasive LIVer And Simultaneous COlorectal Resection N/A
Recruiting NCT03191110 - The COLON Study: Colorectal Cancer Cohort